* P3 Health Partners Inc PIII.OQ PIII.O is expected
to show a
rise in quarterly revenue when it reports results on August 7
for the period ending June 30 2024
* The Chicago Illinois-based company is expected to report
a
16.5% increase in revenue to $383.47 million from $329.09
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
* LSEG's mean analyst estimate for P3 Health Partners Inc
is for
a loss of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for P3 Health
Partners Inc is $2.00, above its last closing price of $0.60.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.11 -0.11 -0.16 Missed -50
Dec. 31 2024 -0.19 -0.11 -0.22 Missed -100
Sep. 30 2023 -0.29 -0.22 -0.12 Beat 45.5
Jun. 30 2023 -0.14 -0.13 -0.09 Beat 30.8
Mar. -0.63 -0.67 -0.22 Beat 67.4
31 2023
Dec. 31 2022 -0.91 -2.26 Missed -148.4
Sep. 30 2022 -0.47 -0.46 -0.27 Beat 41.7
Jun. 30 2022 -0.16 -0.21 Missed -31.2
This summary was machine generated August 6 at 02:06 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)